Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.
Actively Recruiting
Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.
Actively Recruiting
Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of products based on Tribulus terrestris, L. in men diagnosed with oligospermia, a condition characterized by low sperm count. The study focuses on men between 25 and 60 years old who have a sexual partner and an indication for drug treatment involving steroid hormones or related compounds. The trial is a phase 4, randomized, double-blind study comparing different doses of Tribulus terrestris with a placebo. Participants will be randomly assigned to receive one of several study groups Tribulus terrestris at doses of 94 mg, 250 mg, or 280 mg, or a placebo. The treatment period lasts for 3 months, during which participants will take the assigned product as directed. The study is designed to carefully manage any risks while assessing how the products affect sperm quality compared to placebo. During the study, men will undergo evaluations of their spermogram to measure changes in sperm characteristics. Researchers will monitor safety through clinical assessments and laboratory tests, including liver enzyme and creatinine levels. The primary outcome is the effectiveness of each product in improving sperm parameters over the 3-month period. Participants health and well-being will be closely followed throughout the study.
Actively Recruiting
This trial investigates how well a fixed-dose combination of dipyrone monohydrate, caffeine, and chlorpheniramine maleate works to improve symptoms of the common cold and flu in adults aged 18 to 60 years. The study evaluates the safety and effectiveness of this combination compared to an active comparator and a placebo in adults experiencing nasal obstruction and congestion. It aims to provide insight into symptom relief within a few days of treatment. Participants are randomly assigned to one of three groups one receiving 1000 mg dipyrone monohydrate with 60 mg caffeine and 4 mg chlorpheniramine maleate, another receiving a lower dose of these drugs, or a placebo group. The study is double-blind, so neither participants nor researchers know which treatment is given. The treatments are administered as fixed-dose tablets, and the trial is designed to compare the different doses impact on symptom improvement. During the study, participants attend visits where researchers monitor symptoms of nasal obstruction and congestion over three days. They assess how many participants show improvement and record any safety concerns. Participants must comply with study procedures, including not having used other symptomatic treatments and following visit schedules. The total participation period lasts until the primary outcome is assessed at three days after treatment begins, with safety and symptom monitoring throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a new concentration of a fixed-dose combination drug called EF190 in women with moderate acne vulgaris. This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study aims to compare the experimental drug with a placebo over six 28-day treatment cycles in female participants aged 14 to 45 years. The study addresses moderate acne characterized by specific lesion counts and includes participants who have had acne for at least six months. Participants will be randomly assigned in a 21 ratio to receive either the experimental drug, containing cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg in a 24 active plus 4 inactive tablet regimen, or a matching placebo. Both groups will receive treatment for six consecutive 28-day cycles alongside standard skin care. The treatment starts on the 28th day after menstruation. In addition to study drug administration, a subgroup will undergo extra assessments including acne questionnaires, ovarian activity tests, photographic documentation, and special lab and ultrasound exams. Participants will attend five in-person visits screening, randomization, and three follow-ups occurring on day 15 of each treatment cycle. They will also receive three phone calls during cycles 2, 4, and 5 to support adherence, monitor side effects, and ensure contraceptive use. Researchers will measure reductions in inflammatory and total acne lesions and changes in acne severity through clinical assessments and questionnaires. The study includes safety monitoring and aims to complete participation within about 24 weeks.